Status:
UNKNOWN
Early Antibiotic Therapy and Vaccination
Lead Sponsor:
University Hospital Tuebingen
Conditions:
Vaccination Reaction
Eligibility:
All Genders
24-28 years
Brief Summary
Neonatal Sepsis is one of the most common causes of death in preterm infants. Therefore, up to 80% of very low birth weight infants receive antibiotic therapy in their first week of life. Antibiotic t...
Detailed Description
The aim of the study is to compare antibody titers against Hepatitis B, Polio, Pertussis, Haemophilus influenza B, Tetanus, Diphteria and Pneumococcus in very low birth weight infants (VLBWI) infants ...
Eligibility Criteria
Inclusion
- born at University Hospital Tübingen
- at least one dose of antibiotics within the first week of life
Exclusion
- genetic disorders
- chronic infections
- hematological disorders
- immunoglobulins within the first 60 days of life
- immunological disorders
- infants from Hepatitis B positive mothers
Key Trial Info
Start Date :
September 27 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04109833
Start Date
September 27 2019
End Date
October 1 2021
Last Update
September 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Tübingen, Baden-Wurttemberg, Germany, 72076